Strategies towards a longer acting factor VIII

Haemophilia

Volumn 12, Issue SUPPL. 3, 2006, Pages 42-51

  Saenko, E L ^a   Pipe, Steven W ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bioengineering; Clearance; Factor VIII; Half life; Polyethylene glycol; Polysialic acids

Indexed keywords

ADENOSINE DEAMINASE; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HEMOSTATIC AGENT; INSULIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROGOL; PEGINTERFERON; PEGYLATED ADENOSINE DEAMINASE; PEGYLATED BLOOD CLOTTING FACTOR 8; PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR; PEGYLATED GROWTH HORMONE; PEGYLATED LIPOSOMAL BLOOD CLOTTING FACTOR 8; POLYSIALIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; ARTICLE; BIOTECHNOLOGY; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG BINDING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; GENE DELETION; GENE INACTIVATION; HEMOPHILIA; HEMOSTASIS; HEPATITIS; HUMAN; NEUTROPENIA; NONHUMAN; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

CHEMISTRY, PHARMACEUTICAL; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS; MALE; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646147385     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01260.x     Document Type: Article

References (60)

1. Evatt BL, Black C, Batorova A et al. Comprehensive care for haemophilia around the world. Haemophilia 2004; 10 (Suppl. 4): 9-13.
2. Petrini P, Chambost H, Nemes L. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia 2004; 10 (Suppl. 4): 94-6.
3. Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: A resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10 (Suppl. 1): 63-70.
4. O'Mahony B. WFH: Back to the future. Haemophilia 2004; 10 (Suppl. 4): 1-8.
5. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
6. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: Where do we stand? Haemophilia 2004; 10 (Suppl. 4): 97-104.
7. Molineux G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003; 23: 3S-8S.
8. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977; 252: 3578-81.
9. Abuchowski A, McCoy JR, Palczuk NC et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977; 252: 3582-6.
10. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9: 249-304.
11. Zeuzem S, Heathcote JE, Martin N et al. Peginterferon alfa-2a (40 kDa) monotherapy: A novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs 2001; 10: 2201-13.
12. Yoshimoto T, Nishimura H, Saito Y et al. Characterization of polyethylene glycol-modified L -asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res 1986; 77: 1264-70.
13. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005; 10: 1451-8.
14. Bailon P, Palleroni A, Schaffer CA et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195-202.
15. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404.
16. Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL. Catabolism of the coagulation factor VIII: Can we prolong lifetime of fVIII in circulation? Trends Cardiovasc Med 2001; 11: 251-7.
17. Fass DN, Knutson GJ, Katzmann JA. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 1982; 59: 594-600.
18. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268-78.
19. Bihoreau N, Pin S, de Kersabiec AM et al. Copper-atom identification in the active and inactive forms of plasma-derived FVIII and recombinant FVIII-delta II. Eur J Biochem 1994; 222: 41-8.
20. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-12.
21. Fay PJ, Beattie TL, Regan LM et al. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996; 271: 6027-32.
22. Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem 1992; 267: 13246-50.
23. Rostin J, Smeds AL, Akerblom E. B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug Chem 2000; 11: 387-96.
24. Veronese FM. Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 2001; 22: 405-17.
25. Pipe SW, Kaufman RJ. Structural and functional role of the factor VIII B domain. Haematologica 2004; 89: 8-13.
26. Miao HZ, Sirachainan N, Palmer L et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412-19.
27. Baxter International, Inc. Baxter announces collaborations to develop longer acting forms of blood clotting factors. Published online at http://www.baxter.com/about_baxter/news_room/news_releases/2005/ 09-29-05-collaboration.html. Accessed 7 January, 2006.
28. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261-77.
29. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids. Int J Pharm 2005; 300: 125-30.
30. Goyal P, Goyal K, Vijaya Kumar SG et al. Liposomal drug delivery systems - clinical applications. Acta Pharm 2005; 55: 1-25.
31. Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424-36.
32. Kedar E, Braun E, Rutkowski Y et al. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: Immunomodulatory and anti-tumor activity in mice. J Immunother Emphasis Tumor Immunol 1994; 16: 115-24.
33. Baru M, Carmel-Goren L, Barenholz Y et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005; 93: 1061-8.
34. Bayer HealthCare. Bayer completes investigational new drug filing with FDA for longer-acting Kogenate® product. Published online at http://www.bayerhealthcare.com/401.0.html?&L=2&tx_ ttnews[pointer]=4&tx_ttnews[tt_news]=228&tx_ ttnews[backPid]=30&cHash=63f91fd197
35. Fernandes AI, Gregoriadis G. Polysialylated asparaginase: Preparation, activity and pharmacokinetics. Biochim Biophys Acta 1997; 1341: 26-34.
36. Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implication in its pharmacokinetics. Int J Pharm 2001; 217: 215-24.
37. Jain S, Hreczuk-Hirst DH, McCormack B et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta 2003; 1622: 42-9.
38. Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 3: 1692-701.
39. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-6.
40. Pipe SW, Nichols TC, McClintock DWD et al. The conformation of the factor VIII light chain can modulate von Willebrand factor binding affinity without affecting cofactor activity in vitro and in vivo. Blood 1999; 94 (10 Suppl. 1): 453a.
41. Nichols TC, Pipe SW, Kaufman RJ et al. Inactivation-resistant human coagulation factor VIIIa (IR8) corrects canine hemophilia A coagulopathy. Thromb Haemost 1999; 82 (Suppl. Abstracts): 488a.
42. Thornburg CD, Palmer L, Miao HZ et al. Inactivation-resistant factor VIII provides superior hemostasis to wild-type factor VIII in a murine hemophilia A model without increased thrombogenicity. Blood 2003; 102: 88a.
43. Pemberton S, Lindley P, Zaitsev V et al. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-21.
44. Gale AJ, Xu X, Pellequer JL et al. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci 2002; 11: 2091-101.
45. Gale AJ, Pellequer JL, Griffin JH. A novel engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003; 1 (Suppl. 1): OC094.
46. Radtke K-P, Chamberlain D, Griffin JH, Gale AJ. Whole blood thromboelastogram assays demonstrate prolonged factor VIIIa potency for recombinant disulfide bond-stabilized factor VIII variants. Blood 2004; 104: 2976a.
47. Saenko EL, Yakhyaev AV, Mikhailenko I et al. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999; 274: 37685-92.
48. Lenting PJ, Neels JG, van den Berg BM et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 23734-9.
49. Schwarz HP, Lenting PJ, Binder B et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000; 95: 1703-8.
50. Turecek PL, Schwarz HP, Binder BR. In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor. Blood 2000; 95: 3637-8.
51. Bovenschen N, Herz J, Grimbergen JM et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003; 101: 3933-9.
52. Bovenschen N, Mertens K, Hu L et al. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005; 106: 906-12.
53. Neels JG, Bovenschen N, van Zonneveld AJ, Lenting PJ. Interaction between factor VIII and LDL receptor-related protein. Modulation of coagulation? Trends Cardiovasc Med 2000; 10: 8-14.
54. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001; 276: 11970-9.
55. Bovenschen N, Boertjes RC, Van Stempvoort G et al. Low-density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem 2003; 278: 9370-7.
56. Lenting PJ, van de Loo JW, Donath MJ et al. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271: 1935-40.
57. Koszelak ME, Huggins CF, Fay PJ. Sites in the A2 subunit involved in the interfactor VIIIa interaction. J Biol Chem 2000; 275: 27137-44.
58. Stoilova-McPhie S, Villoutreix BO, Mertens K et al. 3-Dimensional structure of membrane-bound coagulation factor VIII: Modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
59. Sarafanov AG, Makogonenko EM, Pechik IV et al. Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein. Biochemistry 2006; 45: 1829-40.
60. Blanchette VS, McCready M, Achonu C et al. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 19-26. (discussion, 26).